Reaction

Wound Dehiscence reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,346 reports · 116 co-occurring drugs

As of the last recalculation, Wound Dehiscence appears in 3,346 FAERS reports alongside 116 co-occurring drug terms. The strongest observed disproportionality signal is BASILIXIMAB (PRR 18.2).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Basiliximab	34	18.2	18.2
Bevacizumab	305	16.8	16.8
Bupivacaine	24	16.1	16.1
Amiodarone Hydrochloride	23	12.8	12.9
Micafungin Sodium	15	11.1	11.1
Cefazolin	16	11.0	11.0
Sirolimus	22	10.2	10.2
Cefazolin Sodium	19	9.9	9.9
Gentamicin	20	9.6	9.6
Baclofen	125	9.3	9.4
Valganciclovir	28	9.3	9.3
Valganciclovir Hydrochloride	28	9.3	9.3
Dronabinol	11	8.5	8.5
Gentamicin Sulfate	21	8.3	8.3
Ado-Trastuzumab Emtansine	11	8.1	8.1
Meropenem	40	7.8	7.8
Mycophenolate Mofetil	163	7.8	7.8
Mycophenolate Mofetil Hydrochloride	163	7.8	7.8
Fondaparinux Sodium	10	7.7	7.7
Zoledronic Acid	47	7.4	7.4
Capecitabine	105	7.3	7.3
Pyrazinamide	11	7.3	7.3
Docusate Sodium - Sennosides	37	7.2	7.2
Torsemide	38	7.2	7.2
Granisetron Hydrochloride	12	7.2	7.2
Linezolid	34	7.2	7.2
Canagliflozin	34	7.1	7.1
Cimetidine	11	7.1	7.1
Vancomycin	64	7.0	7.0
Alendronate Sodium	110	7.0	7.0
Epoetin Alfa	13	6.8	6.9
Chlorhexidine Gluconate	10	6.8	6.8
Irinotecan Hydrochloride	14	6.8	6.8
Vancomycin Hydrochloride	69	6.6	6.6
Valsartan Oral	57	6.6	6.6
Oxaliplatin	77	6.6	6.6
Cortisone Acetate	13	6.6	6.6
Cefepime	15	6.5	6.5
Tacrolimus Ointment 0.1%	126	6.5	6.5
Tacrolimus	157	6.5	6.5
Tacrolimus Extended-Release Capsules	126	6.5	6.5
Lactulose	39	6.4	6.4
Promethazine Hydrochloride	19	6.4	6.4
Fluorouracil Cream, 0.5%	75	6.2	6.2
Leucovorin Calcium	19	6.2	6.2
Fluorouracil	75	6.1	6.2
Valganciclovir Hydrochloride Powder,	12	6.1	6.1
Ampicillin	8	6.0	6.0
Ampicillin Sodium	8	6.0	6.0
Sorafenib	20	6.0	6.0
Sevoflurane	8	6.0	6.0
Rifampin	14	6.0	6.0
Diphenoxylate Hydrochloride And Atropine Sulfate	13	5.9	5.9
Sodium Chloride Tablet	68	5.8	5.9
Sodium Chloride Tablets	68	5.8	5.9
Quinine	8	5.8	5.8
Cefepime Hydrochloride	15	5.8	5.8
Temozolomide	19	5.6	5.6
Enoxaparin Sodium	51	5.6	5.6
Sodium Chloride	69	5.5	5.5
Ganciclovir	9	5.5	5.5
Mycophenolic Acid	28	5.5	5.5
Anti-Thymocyte Globulin (Rabbit)	7	5.4	5.4
Paclitaxel (Aibumin-Bound)	70	5.4	5.4
Granisetron	9	5.3	5.4
Ganciclovir Sodium	9	5.3	5.3
Fluconazole	58	5.2	5.2
Glyburide	20	5.2	5.2
Lenvatinib	27	5.2	5.2
Isoniazid	13	5.0	5.0
Paclitaxel	78	5.0	5.0
Amphotericin B	10	5.0	5.0
Esomeprazole	49	5.0	5.0
Sulfamethoxazole And Trimethoprim	65	4.9	4.9
Prednisolone	136	4.8	4.8
Prednisolone Oral	136	4.8	4.8
Prednisolone Oral Solution	136	4.8	4.8
Everolimus Tablets	13	4.8	4.8
Senna	16	4.7	4.7
Diclofenac Sodium 1%	26	4.6	4.6
Diclofenac Sodium Topical	26	4.6	4.6
Diclofenac Sodium Topical Gel, 1%	26	4.5	4.5
Erlotinib Hydrochloride	9	4.5	4.5
Diclofenac	61	4.5	4.5
Cabozantinib	34	4.4	4.4
Fentanyl	69	4.4	4.4
Ifosfamide	15	4.4	4.4
Metoclopramide Hydrochloride	52	4.2	4.2
Bleomycin Sulfate	7	4.2	4.2
Mycophenilic Acid	14	4.2	4.2
Goserelin	9	4.2	4.2
Pegaspargase	8	4.1	4.1
Metoprolol Succinate Er Tablets	40	4.0	4.0
Sunitinib Malate	25	4.0	4.0
Trastuzumab	42	3.8	3.8
Pertuzumab	16	3.7	3.7
Carboplatin	73	3.6	3.6
Adalimumab	366	3.5	3.5
Eszopiclone	14	3.4	3.4
Thalidomide	19	3.2	3.2
Erlotinib	5	3.2	3.2
Cisplatin	40	3.2	3.2
Rocuronium Bromide	6	3.2	3.2
Upadacitinib	41	3.2	3.2
Hydromorphone Hydrochloride	44	3.0	3.0
Pazopanib Hydrochloride	13	3.0	3.0
Risankizumab-Rzaa	39	3.0	3.0
Rifaximin	9	2.7	2.7
Pemetrexed	9	2.6	2.6
Darbepoetin Alfa	22	2.5	2.5
Docetaxel Anhydrous	27	2.5	2.5
Docetaxel	27	2.5	2.5
Pemetrexed Disodium	14	2.3	2.3
Sevelamer Carbonate	4	2.2	2.2
Atezolizumab	13	2.1	2.1
Crizotinib	4	2.0	2.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.